Delivery Order SPE2DB20D2104-SPE2DB23FU77G
- Not listed
- This federal contract award, valued at $1,769.13, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of LIDOCAINE 5% PATCH 30S, a pharmaceutical product, to support federal healthcare programs. Amerisourcebergen Drug Corp is a subsidiary of the parent company, Cencora, Inc., which is also a for-profit organization. The contract is a Delivery Order under an...
- This federal contract award, valued at $2,021.37, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The award is for the delivery of 4563941538 - LIDOCAINE 5% PATCH 30S, with a completion date of March 13, 2024. The contract is a Delivery Order under a Firm Fixed Price arrangement and does not have a set-aside designation, indicating open competition. Amerisourcebergen Drug Corp is a major pharmaceutical distributor and healthcare...
- This federal contract award, valued at $2,280.85, was issued by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The contract is for the delivery of LIDOCAINE 5% PATCH 30S, a pharmaceutical product. The award is a delivery order under Amerisourcebergen's Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which has a ceiling value of $999,999,999.00 and runs through November 2026. This IDC serves as a...
- This federal contract award, valued at $4,144.00, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The contract is a delivery order with a firm fixed price type and covers the procurement of LIDOCAINE 5% PATCH 30S, a medical product. The contract has an ultimate completion date of February 28, 2024. Amerisourcebergen Drug Corp is a major pharmaceutical distributor and healthcare solutions provider that plays a critical role in...
- This federal contract award, valued at $9,693.84, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract covers the delivery of LIDOCAINE 5% PATCH 30S, a medical product, with a completion date of May 16, 2023. Amerisourcebergen Drug Corp is a subsidiary of the parent company Cencora, Inc., which is a for-profit organization registered in the System for Award Management (SAM.gov). The...
- This federal contract award, valued at $14,614.74, was made by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The contract is for the delivery of 4554257218 - LIDOCAINE 5% PATCH 30S, a pharmaceutical product, with a completion date of July 29, 2021. This is a firm fixed-price delivery order contract, and there is no set-aside designation mentioned. Amerisourcebergen Drug Corp is a major pharmaceutical distributor and healthcare solutions provider...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the delivery of LIDOCAINE 5% PATCH 30S medical products. The contract, valued at $1,194.02, is a firm fixed-price delivery order with a completion date of November 3, 2021. Amerisourcebergen Drug Corp is a subsidiary of the parent company Cencora, Inc., which holds a significant $999,999,999.00 Indefinite Delivery Contract (IDC) with the DLA Troop...
- This federal contract award, valued at $2,299.32, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of the parent company Cencora, Inc. The award is for the delivery of 4558244987 – LIDOCAINE 5% PATCH 30S, a pharmaceutical product. The contract has a firm fixed price and ultimate completion date of August 29, 2022. Amerisourcebergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to...
- This federal contract award, valued at $1,554.69, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The contract is a Delivery Order (DO) to provide LIDOCAINE 5% PATCH 30S, a pharmaceutical product, to the DLA. The contract has a period of performance ending on February 6, 2024 and is a Firm Fixed Price (FFP) agreement. There is no set-aside designation for this award, indicating open competition. Amerisourcebergen Drug Corp is a major...
- This federal contract award, valued at $1,668.75, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The award is for the delivery of 4554652773 - LIDOCAINE 5% PATCH 30S, with a completion date of September 7, 2021. This contract is a Delivery Order under a firm fixed-price arrangement, and it does not have a set-aside designation, indicating open competition. Amerisourcebergen Drug Corp is a...
- SPE2DB20D2104Indefinite Delivery Contract
- SPE2DB20D2104-SPE2DB23FU77GDelivery Order
This federal contract award, valued at $5,384.71, was made by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of 4561740857 - LIDOCAINE 5% PATCH 30S, with a completion date of August 9, 2023. Amerisourcebergen Drug Corp is a subsidiary of Cencora, Inc., a for-profit organization that specializes in supplying pharmaceutical products and medical supplies to federal government agencies, particularly the Department of Defense and Department of Veterans Affairs healthcare systems. The company holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to $999,999,999.00, which serves as a primary vehicle for delivering a comprehensive range of medical commodities to military and veteran healthcare programs. Additionally, Amerisourcebergen maintains a separate IDC with the Department of Justice Federal Bureau of Investigation, valued at up to $750,000, for similar medical products and prescription drugs. This contract award was made through full and open competition, with no set-aside designation.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $5.4k | 8/8/23 |